Jonas S. Moller

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Part of BioMeridian Corp., BioSource, Inc. develops computerized screening devices used to scan the entire body for early detection of irregularities. The company is based in Orem, UT. BioSource was acquired by BioMeridian Corp. on October 21, 1997.

NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC.

Part of Sartorius AG, Sartorius Stedim Biotech GmbH is a German company that produces and sells laboratory equipment used for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is based in Goettingen, Germany. The CEOs are Helge Henning and Michaela Pischke. The company was founded in 2007.

Filtration Technology Corp. manufactures oil and gas field machinery. The firm offers liquid filters for bag housings, including bag filters, pleated bag filters, and max-out conversion systems; liquid filters for cartridge housings, such as cartridge filters, pleated cartridge filters, and alternative replacement filters; and hydrocarbon removal filters, oil/water separation filter systems, and wastewater cleanup systems. It also provides technical services and support, and test and analysis services. The company was founded in 1987 and is headquartered in Houston, TX.

Part of Sartorius AG, Sartorius Stedim BioOutsource Ltd. is a British company that provides contract testing services of biologic drugs and vaccines. The company is based in Glasgow, UK. The company was founded in 2007. The CEO is Hugo de Wit. Sartorius Stedim BioOutsource was acquired by Sartorius Stedim Biotech SA on April 17, 2015.

Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.

Part of Sartorius AG, Sartorius Korea Biotech Co., Ltd. is a South Korean company that provides engineering services. The company is based in Seongnam, South Korea. The company was founded in 2005. Duk-Sang Kim has been the CEO of the company since 2005.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.

Sartorius Stedim Fmt SAS manufactures plastic packaging products. It serves to biopharmaceutical, chemical, food, and academic labs. The firm's product portfolio includes cell analysis, bioreactors, lab filtration, fluid management, and water purification. The company is headquartered in Aubagne, France.

Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark.

Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.

EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA.

Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA.

Albumin Holding ApS is a financial holding Danish company. The private company is based in Frederiksberg, Denmark. The CEO of the company is Joseph Donald deBethizy.

Part of Sartorius AG, Sartorius Stedim North America Holding GmbH provides financial services. The company is based in Goettingen, Germany. The CEO of the German company is Uwe Becker.

Part of Sartorius AG, Sartorius Xell GmbH is a German company that specializes in providing solutions tailored to the specific requirements of cell lines, allowing them to achieve optimal product yields. The company, founded in 2009, is based in Schloß Holte-Stukenbrock, Germany. Xell's expertise lies in developing customized production processes, including cell culture media, feeds, and medical products. The company's team of highly skilled and motivated employees, with diverse scientific backgrounds, emphasizes a strong focus on technology and innovation. Sartorius Xell was acquired by Sartorius Stedim Biotech SA on July 29, 2021.